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Background: Maintenance of the blind-to-treatment allocation is one of the most important means of avoiding
bias in randomised controlled clinical trials. Commonly used methodologies to determine whether patients have
become unblinded to treatment allocation are imperfect. This may be of particular concern in studies where
outcomes are patient-reported, and with products which have a characteristic adverse event profile. We report the
results of an evidence-based statistical approach to exploring the possible impact of unblinding to a
cannabis-based medicine (SativexW) in people with muscle spasticity due to multiple sclerosis.
Methods: All 666 patients included in three Phase III placebo-controlled studies were included in this analysis. The
relationship between factors that might permit patients to identify their treatment allocation and the effect of
treatment on the self-reported primary outcome measure was investigated using a general linear model where the
dependent variable was the change from baseline in patient self-reported spasticity severity, and the various
possible explanatory factors were regarded as fixed factors in the model.
Results: There was no significant relationship between the effect of SativexW on spasticity and the prior use of
cannabis or the incidence of ‘typical’ adverse events. Nor was there any significant relationship between the prior
use of cannabis and the incidence of ‘typical’ adverse events, nor between prior use of cannabis and dose of
SativexW.
Conclusions: There is no evidence to suggest that there was widespread unblinding to treatment allocation in
these three studies. If any patients did become unblinded, then there is no evidence that this led to bias in the
assessment of the treatment difference between SativexW and Placebo for efficacy, adverse events or study drug
dosing. This methodology may be suitable for assessment of the integrity of the blind in other randomized clinical
trials
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In the planning, execution and analysis of clinical trials,
bias may be introduced by a number of factors, one of
which is that patients or investigators in the study have
become aware of their treatment allocation [1,2]. Rando-
mised trials are often designed as “double-blind” in order
to help minimize this source of bias. Lack of blinding is
a particular concern for trials with important subjective
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reproduction in any medium, provided the orWhen blinding is not possible the trial is called “open-
label”. Unblinding within a randomised controlled trial
is unlikely to occur for all patients, in which case it
would be an open-label comparison. When the blind is
broken the patient (or investigator) is certain about the
allocation of treatment. Much more likely is that the
blind is broken for a subset of participants or that there
is a degree of belief (but not certainty) about treatment
allocation, in which case the extent of potential bias
introduced is unclear. When the primary outcome of the
study is an objective measurement, unaffected by the
patient’s or investigator’s knowledge of the treatmentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sessment of efficacy, although bias may then affect the
assessment of adverse effects [3]. On the other hand,
when the outcome measure is a subjective report by the
patient or by the investigator, then both the therapeutic
effect and the adverse event profile may be influenced if
the patient is aware which treatment they are taking [4].
Either way, assessment of the risk/benefit may be subject
to bias.
The maintenance of the blind to treatment allocation
could be compromised in several ways. These include:
1. The occurrence of particular adverse events,
combined with the information given to the patient
on the known adverse event profile, might enable
some patients to deduce they are on a particular
study medication. This possibility may be
exacerbated for patients with previous experience of
similar compounds, using their reactions to these
compounds to influence which study medication
they think they are receiving.
2. The efficacy of a study medication may suggest
which treatment is being received. This possibility is
more likely when the comparator is a placebo or a
known ineffective compound, and the active
medication is effective.
The second of these causes of unblinding is not gener-
ally a serious concern, since if a patient believes that
they are on the active study medication as a result of ef-
ficacy then the presence of unblinding is effectively a
surrogate endpoint for efficacy. Consequently, an ana-
lysis of unblinding that shows more correct ‘guesses’ in
the group with the better outcome is not necessarily an
indication that the blind was broken [3,5-7] .
Despite this, the most widely used methodology to in-
vestigate the success of blinding within a clinical study is
to ask the patient at some point or points during the
study to guess whether they are taking the active or the
placebo preparation. The proportion of correct guesses
is then compared between the treatment groups. But
testing trial participants (or their clinicians) for blindness
at the end of a trial cannot distinguish the failure of
blinding tactics from their correct guesses about which
treatment was received, based on their experiences of
pharmacodynamics, side-effects and trial outcomes [8].
Nonetheless, the possibility of a break in the blind is
sometimes a real concern, especially in trials with a sub-
jectively assessed outcome. This question arose in con-
junction with a group of trials of a medicine to treat
patients with multiple sclerosis.
SativexW (GW Pharma, Ltd, Salisbury, Wiltshire, UK),
is a recently authorised medicine used for the treatment
of spasticity in people with multiple sclerosis, and isderived from an extract of the cannabis plant. Its princi-
pal components are the two major cannabinoids, delta-
9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
In order to avoid the extensive first pass metabolism
associated with the oral use of cannabinoids, it is taken
as a 100 microlitre spray administered to the sub-lingual
and buccal mucosal surfaces. Each spray contains 2.7 mg
THC and 2.5 mg CBD. THC is the psychoactive compo-
nent of SativexW, and is responsible for the psychoactiv-
ity which recreational users of cannabis seek; CBD, on
the other hand, is not psychoactive, and has been shown
to modulate some aspects of the pharmacodynamics of
THC. Both components have a distinct pharmacology,
and together have been shown to relieve spasticity in
people with multiple sclerosis [9-11].
With any medicine containing psychoactive compo-
nents, the presence of central nervous system side
effects may lead the patient into guessing that they are
taking the active medicine. Also, if the patient has previ-
ously experienced the psychoactive effects of cannabis,
there is a possibility that they may ‘recognise’ the active
study medication. This is a phenomenon that may apply
to a range of medicines with a typical CNS side effect
profile, and not only to a cannabis-based medicine.
To explore whether there was evidence of unblinding
in its key efficacy studies, we combined data from three
randomised, parallel-group, placebo-controlled studies
of SativexW in the treatment of spasticity. There had not
in fact been an attempt to assess the success of blinding
during the conduct of those trials. We examined
whether the prior use of cannabis or the experience of
the most typical central nervous system adverse events
were associated with its anti-spasticity efficacy. We also
investigated whether prior use of cannabis predicted the
dose of SativexW to which patients titrated, or their ex-
perience of any of the most typical CNS adverse events.
There is a consensus, eloquently expressed in the
Cochrane review of anti-spasticity agents in multiple
sclerosis [12], that an acceptable efficacy endpoint ‘must
reflect the patient’s daily experience of their spasticity’.
This opinion, taken together with the inadequacy of the
Ashworth Scale [13], means that a patient-reported out-
come measure is the preferred outcome measure in the
assessment of spasticity. The numerical rating scale, pre-
ferred as the primary outcome measure in studies of
pain, has been validated in the assessment of spasticity
due to multiple sclerosis [14,15].
Methods
The analyses of efficacy data used the combined
intention to treat (ITT) (Full Analysis) populations from
three randomised parallel group double-blind trials com-
paring SativexW with placebo. The results of each of
these studies have been separately published, and we will
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included a similar population of patients, each study was
of similar design, and each study used a patient-reported
spasticity severity score as the primary assessment of the
severity of spasticity. In one study [9], the patients
assessed their spasticity on a 0 to 100 mm visual
analogue scale. These data were converted to a 0 to 10
scale by dividing each individual observation by 10. Both
the other studies [10,11] used a patient-reported 0 to 10
Numeric Rating Scale (NRS) on which 0 represented the
complete absence of spasticity and 10 the worst ever
spasticity.
The three studies were combined in a pre-planned
meta-analysis [16] which showed no statistically signifi-
cant study-by-treatment interaction (P >0.1) or hetero-
geneity of variance (P >0.1). Overall, the meta-analysis
showed SativexW to be superior to placebo as assessed
by the change in spasticity severity according to the NRS
at the end of the study (treatment difference of 0.32
units, SE diff = 0.145; 95% CI −0.61 to −0.04; P = 0.026).
Secondary measures of anti-spasticity effect included a
30% responder analysis (OR 1.62; 95% CI 1.15 to 2.28; P =
0.0073), a Patient Global Impression of Change (OR 1.66;
95% CI 1.16 to 2.9: P = 0.0036) and an Ashworth Score
(no significant difference between treatments).
The analyses of adverse events (AEs) and dose of test
medication used study participants who received at least
one dose of study medication (the combined safety
populations). In all of the analyses, imputation for miss-
ing values was not done. Consequently, cases with miss-
ing values were removed from the affected analyses. In
particular, this includes missing values for baseline cov-
ariates (12 participants) and for prior exposure to canna-
bis (1 participant).
The spasticity data were analysed using a general lin-
ear model. The dependent variable was the change from
baseline in mean spasticity assessment. Fixed factors
considered in the models were treatment group (Sati-
vexW/placebo) (TG), prior use of cannabis (Yes/No)
(PC), study (ST), and the interaction terms TG*PC,
TG*ST, PC*ST, TG*PC*ST. Mean baseline spasticity
(BS), measured on a continuous 0 to 10 scale, was
included as a covariate in all models. Models containing
the following terms were fitted sequentially; with each
subsequent model being considered only if the term to
be removed from the current model did not contribute
significantly (P <0.05):
Model 1. BS, ST, PC, TG, TG*PC, PC*ST, TG*ST,
TG*PC*ST
Model 2. BS, ST, PC, TG, TG*PC, PC*ST, TG*ST
Model 3. BS, ST, PC, TG, TG*PC, PC*ST
Model 4. BS, ST, PC, TG, TG*PC
Model 5. BS, ST, PC, TGIn the event of statistically significant interaction
terms, TG*PC*ST, TG*ST or PC*ST, the interpretation
of the analysis was explored further.
The absence of a statistically significant TG*PC inter-
action would suggest that prior use of cannabis has no
association with the assessment of efficacy. Thus, there
would be no evidence to suggest that the treatment dif-
ference differs between prior and non-prior cannabis
users, that is, even if prior users are able to distinguish
between the treatments, this is not likely to have led to
bias in the assessment of efficacy.
At all stages, the interactions were to be carefully eval-
uated to determine whether they are of degree (quantita-
tive) or direction (qualitative), and how they might
influence the treatment contrast.
It is noted that these analyses could have been done
on the three individual studies. However, the studies
were only powered for their primary comparison and
would have lacked power for examining the interaction
terms that are so important to this methodology. In
addition, the issue of blinding was raised in relation to a
regulatory submission, by which time the studies had
already concluded with no possibility of re-sizing them
to provide reasonable power for the assessment of inter-
action. Consequently, it was decided to take this meta-
analytic approach in order to look for systematic evi-
dence of bias and to maximise the power of these
comparisons.
The distribution of the residuals from the final model
was examined for evidence of departures from the mod-
el’s assumptions, and, in particular, the Shapiro-Wilk test
was used to assess the normality of the fitted residuals.
In the event of gross-departures for the underlying
assumptions, the data (response and baseline covariates)
were ranked and these transformed data then analysed
using the same linear model approach.
Distribution of adverse events: prior v naïve cannabis
users
The patients most likely to be able to distinguish
whether they were in the SativexW or placebo groups
were those who had previous exposure to cannabis. This
could manifest itself in a different adverse event profile
between prior and naïve users in the SativexW group
compared with the placebo group. The following adverse
events were listed as potential effects of cannabis on the
Information Leaflet given to patients prior to them giv-
ing informed consent for participating in the studies:
○ dizziness, disturbance in attention, euphoric mood,
disorientation, feeling disconnected, loss of balance,
difficulty with speaking, confusion, worry, paranoia,
fainting, hallucinations, disorientation, poor
concentration and/or forgetfulness, losing touch with
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feeling abnormal or drunk (nervous system
disorders)
○ fatigue, tiredness or drowsiness, weakness, increased
incidence of falling, lethargy (general disorders and
administration site conditions)
○ nausea, dry mouth, diarrhoea, thirst, throat irritation,
feeling sick, being sick, abdominal discomfort,
increase or decrease in appetite, changes in sense of
taste, stinging or discomfort in the mouth and on
the tongue (gastrointestinal disorders)
Consequently, events classified using the Medical Dic-
tionary for Regulatory Activities (MedDRA) into system
organ classes “nervous system disorders”, “general disor-
ders and administration site conditions”, “gastrointes-
tinal disorders” and “psychiatric disorders” were
examined individually where they were reported by at
least 10 patients (using the MedDRA preferred terms) in
the analysis; events that occurred in fewer than 10
patients were considered to be too rare to provide reli-
able results.
The number of patients reporting these adverse
events, by preferred term, was summarised across the
included studies and displayed by treatment group and
prior/naïve cannabis use within the treatment group.
The odds ratio for patients having received SativexW (as
opposed to placebo) for both prior cannabis users and
cannabis naïve users was calculated for each AE together
with 95% confidence intervals.
Also, for each of these events, a logistic model was
used to assess the odds ratio (SativexW/Placebo) adjusted
for prior cannabis exposure. Fixed factors included in
the model were treatment group (SativexW/placebo)
(TG), Prior use of cannabis (Yes/No) (PC), Study (ST),
and the interaction terms TG*PC, TG*ST, PC*ST,
TG*PC*ST. The TG*PC interaction and PC main effect
were to be inspected for evidence of an association be-
tween prior cannabis exposure and the adverse event
profile, either as an interaction with treatment group or
independent of treatment. If the TG*PC interaction was
statistically significant then that would provide evidence
of possible unblinding. If it were not, but the main effect
of PC in the model excluding the TG*PC interaction was
statistically significant, this would suggest that more (or
fewer) prior cannabis users experienced the event than
cannabis naïve patients. But it would not provide evi-
dence that they would be more likely to identify their
study treatment. The TG term was to be inspected for
evidence of a differential adverse event profile between
the treatment groups. Again, if it was statistically signifi-
cant it would not necessarily provide evidence of
unblinding. Odds ratios and 95% CIs were to be pre-
sented, as appropriate.Association between the experience of central nervous
system events and assessment of efficacy
The association of the three most frequently occurring
central nervous system adverse events and the assess-
ment of efficacy was investigated using the assessment
of spasticity over the primary period during the three
studies.
As in the previous analysis, the data were analysed
using a general linear model. The dependent variable
was the change from baseline in spasticity assessment.
Fixed factors included in the model were treatment
group (SativexW/placebo) (TG), experienced one or more
of the three AEs (Yes/No) (AE), study (ST), and the
interaction terms TG*AE, TG*ST, AE*ST, TG*AE*ST.
Baseline spasticity (BS) was included as a covariate in all
models. The same stepwise model selection process
described above (with the term PC replaced by AE) was
completed.
The interpretation of these analyses would be that if
the occurrence of one of the three most frequent CNS
AEs has no association with the assessment of efficacy,
this would be evidenced by no statistically significant
TG*AE interaction. Thus, there would be no evidence to
suggest that the treatment difference is itself different
for patients who had experienced at least one of these
events, that is, even if patients experiencing these events
realise which treatment they are taking, it is not likely to
have led to bias in the assessment of efficacy.
Dose of test medication: prior v naïve cannabis users
In each of the studies, participants titrated to their own
preferred daily dose (number of sprays) of study medica-
tion. This was done by titrating the doses until satisfac-
tory symptom relief was obtained or until unwanted
side-effects occurred. If prior use of cannabis allowed
patients to determine which medication they have been
given then it might be expected that their titrated dose
would be different from cannabis naïve patients; for ex-
ample, in the placebo treatment group patients with pre-
vious exposure to cannabis might take fewer doses than
the cannabis naïve patients if they realised that they
were on a placebo (futility), especially given that the al-
cohol in the excipients is known to cause oral mucosal
stinging in some study participants.
A general linear model was used exactly as for prior
cannabis use in relation to efficacy with the exceptions
that the dependent variable was to be the patients’ mean
sprays per day of test medication during the studies and
there was no baseline covariate. The interpretation of
these analyses would be that if prior cannabis exposure
has no association with the sprays of test medication
used, as evidenced by no statistically significant TG*PC
interaction, then any unblinding as a result of prior ex-
posure to cannabis is not likely to have led to a different























TG*PC 0.962 0.637 0.561 0.626







Previous users: −1.23 (−1.43 to −1.04)
No previous use: −0.98 (−1.22 to −0.74)
Estimated difference: −0.25 (−0.56 to 0.05)
Summary of ANOVA.
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naïve patients.
In all of these analyses no formal adjustment was
made for the multiplicity involved in considering such a
large number of analyses, with a 5% significance level to
be used for each individual analysis. This multiplicity
needs to be considered when interpreting the above
results.
Results
A total of 666 people with spasticity were randomised
and treated in the three studies to form the safety popu-
lation: 363 to SativexW and 303 to Placebo. The ITT
population comprised 652 patients: 356 on SativexW and
296 on Placebo. Table 1 shows the breakdown by indi-
vidual study for the ITT population.
Association between prior use of cannabis and
assessment of efficacy
Overall, the proportion of patients with prior experience
of cannabis was fairly similar between the two treatment
groups: 117/356 (33%) in the SativexW group and 106/
296 (36%) in the Placebo group, although there was
some variability between studies. Table 1 shows the
breakdown by individual study in the ITT population.
Overall, the proportion of patients reporting prior use of
cannabis (34%) is slightly lower than the 43% reported in
the literature [12].
The results of Model 1 using ANOVA showed that the
three-way interaction, TG*PC*ST was not statistically
significant (P = 0.19) and it was removed. Neither of the
two-way interactions involving study, TG*ST and PC*ST,
were statistically significant (P = 0.72, 0.51 and Models 2
and 3, respectively) and so were removed. The model
(Model 4) containing baseline spasticity, the main effects
ST, PC, TG and the two-way interaction TG*PC showed
that the interaction TG*PC was not statistically signifi-
cant (P = 0.63). Model 5, containing only baseline spasti-
city and the main effects ST, PC and TG, showed that
the main effect of prior use of cannabis was not statisti-
cally significant overall (P = 0.11). These results are
summarized in Table 2.
The residuals from the model containing baseline
spasticity, the main effects ST, PC, TG and the two-wayTable 1 The ITT populations with and without prior
cannabis use in each of the studies
SativexW (n = 356) Placebo (n = 296) Total (n = 652)
PC No PC PC No PC PC No PC
Study
GWCL0403 33 133 47 122 80 255
GWMS0001 33 37 32 30 65 67
GWMS0106 51 69 27 37 78 106interaction PC*TG were clearly not Normally distributed
(Shapiro-Wilk W test: P <0.0001). Accordingly, a non-
parametric rank analysis of covariance was performed
using the ranks for the baseline spasticity and change
from baseline. The results were very similar to the para-
metric analyses using the observed data – two-way inter-
action TG*PC was not statistically significant (P = 0.37),
and the main effect of prior cannabis use was not statis-
tically significant (P = 0.16).
In summary, we found no statistical evidence of a rela-
tionship between efficacy and prior use of cannabis ei-
ther overall or between the treatment groups.Distribution of adverse events: prior v naïve cannabis
users
The analysis of the distribution of AEs between prior
cannabis users and cannabis naïve patients used the
Safety population. Overall the proportion of patients
with prior experience of cannabis was fairly similar be-
tween the two treatment groups: 121/363 (33%) in the
SativexW group and 110/303 (36%) in the Placebo group.
After consolidating the AEs described, there were 135
different preferred terms (34 in “gastrointestinal disor-
ders”, 23 in “general disorders and administration site
conditions”, 45 in “nervous system disorders” and 33 in
“psychiatric disorders”). Twenty-five of them occurred in
10 or more patients. For this analysis the most import-
ant model is the one comprising ST PC TG TG*PC. For
the 13 AEs where the number of patients experiencing
the event was 20 or more, this model always converged.
When the number of patients experiencing a particular
AE was less than 20, sometimes this model did not
Table 3 AEs by treatment and prior experience of cannabis (where n >/= 10)
Body system Preferred term SativexW Placebo OR (95% CI)
n n (%) n (%)
Nervous system disorders Dizziness PC 32 (26%) 13 (12%) 2.7 (1.3 to 5.4)
n = 150 No PC 84 (35%) 21 (11%) 4.33 (2.6 to 7.3)
Headache PC 9 (7%) 14 (13%) 0.55 (0.2 to 1.3)
n = 57 No PC 21 (9%) 13 (7%) 1.31 (0.6 to 2.7)
Somnolence PC 17 (14%) 3 (3%) 5.8 (1.7 to 20.5)
n = 45 No PC 19 (8%) 6 (3%) 2.6 (1.0 to 6.7)
Muscle spasticity PC 2 (2%) 2 (2%) 0.9 (0.1 to 6.6)
n= 33 No PC 17 (7%) 12 (6.3%) 1.1 (0.5 to 2.4)
Balance disorder PC 6 (5%) 3 (2.7%) 1.9 (0.5 to 7.6)
n = 20 No PC 8 (3%) 3 (2%) 2.2 (0.6 to 8.2)
Disturbance in attention PC 7 (6%) 0
n = 19 No PC 12 (5%) 0
Dysgeusia PC 3 (3%) 1 (1%) 2.8 (0.3 to 27.0)
n= 18 No PC 13 (5%) 1 (0.5%) 10.8 (1.4 to 83.6)
MS relapse PC 0 2 (1.8%)
n = 17 No PC 8 (3%) 7 (4%) 0.9 (0.3 to 2.5)
Dysarthria PC 5 (4%) 0
n = 13 No PC 2 (3%) 2 (1%) 2.4 (0.5 to 12.1)
Psychiatric disorders Disorientation PC 9 (7%) 1 (1%) 8.8 (1.1 to 70.3)
n = 21 No PC 10 (4%) 1 (0.5%) 8.2 (1.0 to 64.9)
Depression PC 5 (4%) 3 (3%) 1.5 (0.4 to 6.6)
n = 19 No PC 8 (3%) 3 (2%) 2.2 (0.6 to 8.2)
Euphoria PC 3 (3%) 3 (3%) 0.9 (0.2 to 4.6)
n = 13 No PC 4 (2%) 3 (2%) 1.1 (0.2 to 4.8)
Insomnia PC 0 1 (1%)
n = 10 No PC 4 (2%) 5 (3%) 0.6 (0.2 to 2.4)
General disorders Fatigue PC 17 (14%) 9 (8%) 1.8 (0.8 to 4.3)
n = 107 No PC 50 (21%) 31 (17%) 1.4 (0.8 to 2.2)
Application site pain PC 6 (5%) 6 (6%) 0.9 (0.3 to 2.9)
n = 34 No PC 12 (5%) 10 (5%) 0.9 (0.4 to 2.2)
Asthenia PC 9 (7%) 7 (6%) 1.2 (0.4 to 3.3)
n = 45 No PC 22 (9%) 7 (4%) 2.6 (1.0 to 6.8)
Feeling abnormal PC 5 (4%) 1 (1%) 4.7 (0.5 to 40.9)
n = 12 No PC 5 (2%) 1 (1%) 4 (0.5 to 34.8)
Feeling drunk PC 3 (3%) 0
N = 11 No PC 8 (3%) 0
GastroIntestinal Disorders Oral discomfort PC 12 (10%) 10 (9%) 1.1 (0.5 to 2.7)
n = 45 No PC 13 (5%) 10 (5%) 1.0 (0.4 to 2.4)
Nausea PC 12 (10%) 8 (7%) 1.4 (0.6 to 3.6)
n = 67 No PC 32 (13%) 15 (8%) 1.8 (0.9 to 3.4)
Dry mouth PC 6 (5%) 6 (6%) 0.9 (0.3 to 2.9)
n = 37 No PC 21 (9%) 4 (2%) 4.5 (1.5 to 13.2)
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Table 3 AEs by treatment and prior experience of cannabis (where n >/= 10) (Continued)
Diarrhoea PC 8 (7%) 7 (6%) 1.0 (0.4 to 3.0)
n = 30 No PC 12 (5%) 3 (2%) 3.3 (0.9 to 11.8)
Vomiting PC 2 (2%) 1 (1%) 1.8 (0.2 to 20.5)
n = 16 No PC 7 (3%) 6 (3%) 0.9 (0.3 to 2.8)
Constipation PC 5 (4%) 3 (3%) 1.5 (0.4 to 6.6)
n = 15 No PC 7 (3%) 0
Dyspepsia PC 1 (1%) 2 (2%) 0.5 (0.0 to 5.0)
n = 14 No PC 7 (3%) 4 (2%) 1.4 (0.4 to 4.9)
Table 4 Analysis of Efficacy adjusting for the three most
frequent Nervous System Disorder AEs – summary of
ANOVA
P-values
Source Model 1 Model 2 Model 3 Model 4
Baseline severity (BS) <0.0001
Study (ST) 0.15
Adverse event (AE) 0.49
Treatment group (TG) 0.033
AE*ST 0.008 0.011 0.010 0.017





spasticity NRS (95% CI)
Previous users: −1.08 (−1.35 to −0.82)
No previous use: −1.20 (−1.38 to −1.01)
Estimated difference: −0.11 (−0.44 to 0.21)
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ST PC TG did converge, and sometimes neither model
converged.
Table 3 summarises the number of patients reporting
these 25 most common AEs, by the preferred term,
across the included studies and displayed by treatment
group and prior/naïve cannabis use within each treat-
ment group. This table is ordered by system organ class.
The odds ratio for patients having received SativexW (as
opposed to placebo) for both prior cannabis users and
cannabis naïve patients are presented for each AE to-
gether with 95% confidence intervals.
For none of these 25 most common AEs were the
three-way TG*PC*ST interaction or either of the two-
way PC*ST and TG*ST interactions statistically signifi-
cant at the 5% level. The TG*PC interaction was not sig-
nificant for any AE. When the TG*PC interaction was
removed and the model contained only the main effects,
there was only one AE where the effect of PC was statis-
tically significant at the nominal 5% level (Somnolence:
P = 0.017).
In summary, there was no significant relationship be-
tween any AE (apart from potentially somnolence) and
prior use of cannabis, and there is no suggestion of a dif-
ferent influence of prior cannabis use between the active
and placebo groups.
Association between central nervous system events and
the assessment of efficacy
The three most common nervous system disorder AEs
were dizziness, headache and somnolence, occurring in
150 (23%), 57 (9%), 45 (7%) of patients, respectively.
There was a notably increased risk of dizziness on Sati-
vexW over placebo for each of the three studies, as well
as overall. Overall, somnolence was also more likely to
be experienced by patients on SativexW, whilst there was
no evidence of a difference between the treatment
groups in the likelihood of experiencing headache either
for the individual studies or overall. Taking the three
events together, then overall patients on SativexW were
more likely to experience at least one of these events
than those on placebo.The modelling (Model 1) showed that the three-way
interaction, TG*AE*ST, was not statistically significant
(P = 0.69) and it was removed. The two-way interaction
TG*ST was also not statistically significant (P = 0.79,
Model 2) and was removed. In the model containing the
two remaining two-way interactions (Model 3) AE*ST
was statistically significant (P = 0.01) while TG*AE was
not (P = 0.13). So next, the two-way interaction TG*AE
was removed (Model 4); the final model contained base-
line spasticity, the main effects ST, AE, TG and the sta-
tistically significant two-way interaction AE*ST (P =
0.017). Table 4 shows a brief summary of the analysis of
these models.
In study GWCL0403, there was no marked difference
between the two AE groups. In study GWMS0001, there
appeared to a greater reduction in spasticity in the
groups experiencing none of the AEs, while in study
GWMS0106, the greater reduction in spasticity appeared
to be in the group which experienced one or more of
the AEs. These differences were statistically significant
(P = 0.017). There was no evidence of a difference in the
predicted means for the treatment group by AEs cross-
classification (P = 0.13).
Table 6 Relationship between prior use of cannabis and





















TG*PC 0.66 0.70 0.64 0.77







Previous users: 13.9 (13.0 to 14.9)
No previous use: 14.4 (13.6 to 15.1)
Estimated difference: 0.43 (−0.76 to 1.61)
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spasticity, the main effects ST, AE, TG and the two-way
interaction ST*AE were clearly not Normally distributed
(Shapiro-Wilk W test: P <0.0001). Accordingly, a non-
parametric rank analysis of covariance was performed
using the ranks for the baseline spasticity and change
from baseline. The results were a little different from the
analyses using the observed data; two-way interaction
ST*AE was not statistically significant in the model con-
taining AE*ST and TG*AE (P = 0.12). When AE*ST was
removed, TG*AE was not statistically significant (P =
0.26) and when this interaction was removed, the main
effect AE was not statistically significant (P = 0.87).
In summary, there is no evidence of a relationship be-
tween overall treatment effect and experience of one or
more of these three AEs. There was some statistical evi-
dence, when using the regular ANCOVA, that the rela-
tionship between efficacy and experience of one of these
AEs was different between the studies but in different
directions in different studies; a supporting non-
parametric analysis did not confirm the presence of a
relationship between efficacy and the study by AE ex-
perience interaction. So, overall there is no evidence that
experiencing one or more of these AEs is associated
with the change from baseline in spasticity in any con-
sistent way.Dose of test medication: prior v naïve cannabis users
Table 5 shows the mean sprays per day of test medica-
tion by treatment group, study and prior use of cannabis.
Table 6 shows a brief summary of the models fitted to
these data. Model 1 showed that the three-way inter-
action, TG*PC*ST, was not statistically significant (P =
0.23) and it was removed. The two-way interaction,Table 5 Mean number of daily doses taken by patients in







GWCL0403 SativexW PC 33 8.47 5.06
No PC 133 8.49 4.70
Placebo PC 47 14.69 6.34
No PC 122 15.67 6.08
GWMS0001 SativexW PC 33 13.78 10.2
No PC 37 13.27 7.66
Placebo PC 32 21.72 11.15
No PC 30 24.75 10.83
GWMS0106 SativexW PC 51 8.97 7.04
No PC 69 9.79 6.02
Placebo PC 27 15.83 9.37
No PC 37 14.70 7.59PC*ST (Model 2), was also not statistically significant
(P = 0.90) and was removed. In the model containing
the two remaining two-way interactions, (Model 3)
ST*PC and TG*PC, ST*PC was close to being statisti-
cally significant (P = 0.058) while TG*PC was not (P =
0.64). After TG*ST was removed TG*PC was not signifi-
cant (P = 0.77, Model 4) and was removed. In the model
with only main effects (Model 5), PC was not significant
(P = 0.48) and was removed. In both treatment groups;
there was little difference between the previous users
and the cannabis naïve patients.
The residuals from the model containing baseline
spasticity, the main effects ST, PC, TG and the two-way
interaction TG*ST, were clearly not Normally distributed
(Shapiro-Wilk W test: P <0.0001). Accordingly, a non-
parametric rank analysis of covariance was performed
using the ranks for the baseline spasticity and change
from baseline. The results were fairly similar to the ana-
lyses using the observed data, except that the two-way
interaction TG*ST was clearly not statistically significant
(P = 0.30). In summary, no interaction involving prior
use of cannabis was statistically significant, nor was the
main effect when the interactions were removed. This
suggests that the dosing of study medication was not
affected by prior use of cannabis.Discussion
The results of our analysis show that neither prior ex-
perience of cannabis, nor the occurrence of the most
common CNS adverse events has a significant effect on
the change in subjective patient-reported spasticity se-
verity score in a large cohort of patients with multiple
sclerosis treated with SativexW. This allows for the con-
clusion that there is no evidence that any unblinding
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have affected the outcome. This is an important contri-
bution to confirming the internal validity and scientific
integrity of the three randomized controlled studies
which contributed to our analysis.
In a controlled, double-blind clinical study, unblinding
of patients to treatment allocation has the potential to
introduce bias into the results, most notably where the
outcome measures are subjective [4]. The most appro-
priate means by which to assess whether patients have
become unblinded to treatment allocation is the subject
of some debate. The most frequently used approach is
simply to ask patients to guess which treatment they are
taking, and to describe and assess the statistical signifi-
cance of the results. Indeed, this approach has been
strongly endorsed. However, there is no accepted best
practice on how to ask the question, nor how to analyse
the results [17,18].
While the most commonly employed approach is to
ask the patient at the end of the study, other approaches
ask at the beginning of the study, or both at the begin-
ning and the end. Some methods permit a ‘don’t know’
response, while others do not. The statistical method-
ology used to assess the significance of the guesses also
varies, with a Chi square or Fisher’s exact test being the
most frequently employed [17]. Alternatively, James
et al. [19] and, subsequently, Bang et al. [20] have pro-
posed a ‘blinding index’, which aims to provide a more
systematic and consistent way of dealing with guesses
regarding treatment allocation. In one published study
of a different cannabis-based medicine than has been
investigated in this report, patients were asked to guess
their treatment allocation, and there was evidence that
they did so to a greater degree than expected [21]. In
that study, the rate of nervous system adverse events
was also substantially higher than was seen in the three
studies we report. While the authors of that study inter-
preted the results of the treatment guesses as an indica-
tion that patients were unblinded, we would propose
that it might have been a reflection of greater efficacy. A
systematic study of the impact of unblinding on patients’
and physicians’ judgement of the effect of a treatment
on multiple sclerosis was published in a classic paper by
Noseworthy et al. [22]. That study suggested that the
impact of being unblinded to treatment was greater
when the physician was unblinded than when the patient
was unblinded.
In all these cases, the fundamental problem of how to
interpret the patients’ guesses remains; a correct guess
may be a surrogate for the efficacy of a medicine with a
subjective outcome measure, or an indication that the
medicine has a characteristic adverse event profile. In-
deed, it is questionable whether such data can provide
valid information about possible unblinding [7,8].In the analysis that we report here, there was little evi-
dence that experience of any of the three most common
nervous system adverse events was associated with the
change from baseline in the patient-reported severity of
spasticity. If the patients had become unblinded by the
adverse event, then it would be expected that such
unblinding may have led to an overestimation by the pa-
tient of the efficacy, since they would be more likely to
believe that they were on active treatment. Similarly, effi-
cacy was no greater in those patients who reported prior
use of cannabis; were the patients able to ‘recognise’ the
cannabis-based medicine because of prior experience of
cannabis, then it might be expected that they would
overestimate the effects of treatment – and they did not.
The observation that patients with prior experience of
cannabis did not show a different dosing pattern of
study medication helps confirm that they were unlikely
to have been unblinded as a result of their prior
experience.
The approach we have adopted has limitations. For ex-
ample, it is feasible that even if patients do become
aware of their treatment allocation, this might not affect
their assessment of the impact of the medicine on their
condition. Or even that awareness of their treatment al-
location may predispose them to lack of efficacy or to
report particular adverse events, depending on their ex-
pectation of the effects of the active treatment. For this
reason, we believe that the kind of analysis that we have
done here is better designed to determine not so much
whether unblinding is likely to have occurred, but
whether any unblinding that may have occurred is likely
to have had an impact on the outcome. Our approach
also assumes that patients who become unblinded to
treatment allocation are likely to express bias in the way
they assess the efficacy of the treatment in a similar way.
It remains possible that sub-groups of patients may have
become unblinded to treatment allocation, and that this
unblinding may have affected their assessment of the ef-
ficacy of the treatment in opposite directions, thus
resulting in no overall impact of unblinding. It is not
possible to detect whether this may have occurred.
This discussion also raises questions about what really
constitutes effectiveness. In the setting of clinical medi-
cine, the patient is of course always aware of their treat-
ment allocation, and yet the prescriber is generally
willing to accept their report of the effectiveness of the
treatment. It is perhaps paradoxical that we are prepared
to accept the patient report in the setting of the thera-
peutics of a condition in clinical practice, but not in the
setting of a clinical trial.
Despite this, there is little doubt that maintaining the
integrity of the blind in a double-blind study contributes
to the internal validity of the study, even if the external
validity may be limited. Equally, it seems clear that the
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maintenance of the blind is limited. Therefore, there
exists a need for alternative approaches to investigating
this source of potential bias in the setting of the rando-
mized controlled clinical study.
Because of this, we took what we believe to be the
more rigorous approach whereby we first identified the
likely factors that might lead to unblinding, and then
systematically investigated the impact of those factors on
the subjective outcome of the studies. This approach
avoids the paradox described by Fisher in his definitive
essay ‘Mathematics of a Lady Tasting Tea’ [23], whereby
the fact that the study participants correctly guess their
treatment allocation reflects the difference between
treatments, and is regarded as invalidating the study,
and at the same time validates the study hypothesis that
the treatments are indeed distinguishable [5]. Our ap-
proach also concentrates on the impact that possible
unblinding has on the study outcome, rather than de-
scribing the patients’ views on the treatment that they
received. In this way, our methodology adds directly to
the credibility of the outcome. We believe that this
methodology can be applied to studies of a variety of
study medications, particularly where there is a subject-
ive primary outcome measure, and where the drug has a
distinct adverse event profile.Conclusions
We are able to conclude from this investigation that the
presence of factors which might be assumed to lead to
unblinding of some patients to their treatment alloca-
tion, had no significant impact on the subjective efficacy
endpoint used in three separate placebo-controlled clin-
ical trials of a cannabis-based medicine. This suggests
not only that widespread unblinding was unlikely, but
also that what unblinding may have occurred did not
introduce bias into the assessment of the efficacy of Sati-
vexW in the relief of spasticity due to multiple sclerosis.
We propose that this methodology is suitable for the in-
vestigation of potential bias of other medicines with a
characteristic adverse event profile, and where efficacy is
assessed using subjective measures.Abbreviations
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